Rezolute, Inc. (NASDAQ:RZLT) Insider Brian Kenneth Roberts Buys 2,500 Shares

Rezolute, Inc. (NASDAQ:RZLT - Get Free Report) insider Brian Kenneth Roberts bought 2,500 shares of the stock in a transaction that occurred on Wednesday, June 25th. The shares were purchased at an average price of $4.38 per share, with a total value of $10,950.00. Following the completion of the acquisition, the insider now directly owns 15,500 shares in the company, valued at $67,890. This trade represents a 19.23% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Rezolute Stock Up 0.9%

Rezolute stock traded up $0.04 during trading on Friday, reaching $4.35. The stock had a trading volume of 10,248,992 shares, compared to its average volume of 629,654. Rezolute, Inc. has a 52-week low of $2.22 and a 52-week high of $6.19. The stock has a market cap of $372.01 million, a PE ratio of -3.78 and a beta of 1.04. The business has a 50 day moving average price of $3.98 and a 200 day moving average price of $4.07.

Rezolute (NASDAQ:RZLT - Get Free Report) last announced its quarterly earnings data on Tuesday, May 13th. The company reported ($0.27) earnings per share for the quarter, missing analysts' consensus estimates of ($0.22) by ($0.05). On average, equities analysts predict that Rezolute, Inc. will post -0.93 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on RZLT. Wall Street Zen downgraded shares of Rezolute from a "hold" rating to a "sell" rating in a research note on Thursday, May 22nd. HC Wainwright reaffirmed a "buy" rating and set a $14.00 price objective on shares of Rezolute in a research report on Monday, April 28th. Finally, Wedbush reiterated an "outperform" rating and issued a $12.00 price objective on shares of Rezolute in a research note on Wednesday, May 14th. One equities research analyst has rated the stock with a sell rating, six have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, Rezolute currently has an average rating of "Moderate Buy" and a consensus target price of $11.83.

Institutional Trading of Rezolute

A number of hedge funds and other institutional investors have recently bought and sold shares of RZLT. Adage Capital Partners GP L.L.C. boosted its position in shares of Rezolute by 699.7% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 2,525,883 shares of the company's stock worth $12,377,000 after acquiring an additional 2,210,038 shares in the last quarter. Woodline Partners LP lifted its stake in Rezolute by 2,817.1% during the fourth quarter. Woodline Partners LP now owns 1,089,345 shares of the company's stock worth $5,338,000 after purchasing an additional 1,052,002 shares during the last quarter. Susquehanna International Group LLP lifted its stake in Rezolute by 749.0% during the fourth quarter. Susquehanna International Group LLP now owns 893,601 shares of the company's stock worth $4,379,000 after purchasing an additional 788,349 shares during the last quarter. Walleye Capital LLC acquired a new position in Rezolute in the fourth quarter valued at approximately $2,408,000. Finally, Nantahala Capital Management LLC increased its stake in Rezolute by 10.9% in the fourth quarter. Nantahala Capital Management LLC now owns 2,857,982 shares of the company's stock valued at $14,004,000 after purchasing an additional 280,861 shares during the last quarter. 82.97% of the stock is currently owned by institutional investors and hedge funds.

Rezolute Company Profile

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.